```html

Warm Autoimmune Hemolytic Anemia (WAIHA)

Overview

Warm autoimmune hemolytic anemia (WAIHA) is a type of acquired hemolytic anemia in which the body’s immune system produces antibodies that bind to red blood cells (RBCs) at body temperature (≈37 °C). These “warm” antibodies—most commonly IgG—mark the cells for destruction by the spleen and liver, leading to premature RBC loss (hemolysis).

WAIHA can occur as an isolated (primary) disease or secondary to other conditions such as lymphoproliferative disorders, autoimmune diseases, infections, or certain medications.

• Typical age of onset: Bimodal—children (often after viral infections) and adults aged 50‑70 years.
• Gender: Slight female predominance (≈55 % of cases).
• Prevalence: Autoimmune hemolytic anemia (AIHA) overall affects ~1–3 per 100,000 people per year; warm type comprises 70‑80 % of AIHA cases [1][2].

Symptoms

Because hemolysis can be slow or rapid, symptoms vary from subtle fatigue to life‑threatening anemia. Common manifestations include:

General

• Fatigue & weakness: Due to reduced oxygen‑carrying capacity.
• Shortness of breath: Especially on exertion.
• Palpitations or rapid heart rate (tachycardia).
• Headache, dizziness, or fainting spells.

Signs of Hemolysis

• Jaundice: Yellowing of the skin and sclera from bilirubin buildup.
• Dark urine (cola‑colored): Hemoglobinuria from intravascular hemolysis.
• Splenomegaly: Enlarged spleen felt in the left upper abdomen.
• Fever: May indicate an underlying infection or an active immune response.
• Acute abdominal pain: Can occur with splenic sequestration.

Skin & Mucosal Findings

• Gallstones: Chronic bilirubin elevation predisposes to pigment stones.
• Pruritus: Cholestatic pruritus from high bilirubin.
• Palmar erythema or peripheral cyanosis: In severe anemia.

Other

• Weight loss & loss of appetite.
• Night sweats: Especially when WAIHA is secondary to lymphoma.

Causes and Risk Factors

WAIHA is usually immune‑mediated rather than inherited. The underlying cause can be classified as:

Primary (Idiopathic) WAIHA

• Autoantibody production without an identifiable trigger; accounts for ~30‑40 % of cases.

Secondary WAIHA

Occurs in the setting of another disease or exposure:

• Lymphoproliferative disorders: Chronic lymphocytic leukemia (CLL), non‑Hodgkin lymphoma (≈10‑20 % of secondary cases).
• Autoimmune diseases: Systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome.
• Infections: Mycoplasma pneumoniae, Epstein‑Barr virus, HIV, and occasionally COVID‑19.
• Medications: Alpha‑methylsuccinate, penicillins, cephalosporins, methyldopa, and some anti‑cancer agents can act as haptens, prompting antibody formation.
• Transplant‑related: Hematopoietic stem cell transplantation (immune reconstitution).

Risk Factors

• Age >50 years (higher likelihood of secondary causes).
• Female gender (modest increase).
• Previous exposure to high‑risk drugs or a known autoimmune condition.
• Family history of other autoimmune diseases (suggests overall immune dysregulation).

Diagnosis

Diagnosing WAIHA requires a combination of clinical suspicion, laboratory testing, and exclusion of other anemia causes.

Baseline Laboratory Evaluation

• Complete blood count (CBC): Low hemoglobin (often <10 g/dL), elevated reticulocyte count (>2 % – reflecting marrow compensation).
• Lactate dehydrogenase (LDH): Elevated due to RBC destruction.
• Indirect bilirubin: Increased (unconjugated bilirubin).
• Haptoglobin: Decreased or undetectable (binds free hemoglobin).
• Peripheral smear: Spherocytes, polychromasia, occasional nucleated RBCs; no schistocytes (distinguishes from microangiopathic hemolysis).

Direct Antiglobulin Test (DAT, Coombs Test)

Essential for confirming autoimmune hemolysis. In warm AIHA, the DAT is typically positive for IgG (± C3d). A positive DAT with only IgG specificity virtually clinches the diagnosis.

Additional Tests to Identify Secondary Causes

• Serology for HIV, hepatitis B/C, Mycoplasma.
• Autoimmune panel: ANA, anti‑dsDNA, rheumatoid factor.
• Flow cytometry or bone‑marrow biopsy if lymphoproliferative disease is suspected.
• Drug history review to rule out drug‑induced AIHA.

Imaging

Ultrasound or CT of the abdomen may be performed to assess splenomegaly or detect lymphadenopathy.

Diagnostic Criteria (simplified)

1. Laboratory evidence of hemolysis (low haptoglobin, high LDH, indirect bilirubin, reticulocytosis).
2. Positive DAT for warm IgG antibodies.
3. Exclusion of other hemolytic processes (e.g., G6PD deficiency, sickle cell disease).

Treatment Options

Treatment strategy balances rapid control of hemolysis with long‑term disease management. Therapy is individualized based on severity, underlying cause, and patient comorbidities.

First‑Line Pharmacologic Therapy

• Corticosteroids: Prednisone 1 mg/kg/day (max 80 mg) for 2‑4 weeks, then taper based on response. Steroids reduce antibody production and macrophage activity.
• Response rates: ~70‑80 % achieve hemoglobin stabilization within 2‑4 weeks [3].

Second‑Line / Steroid‑Sparing Options

1. Rituximab (anti‑CD20 monoclonal antibody):
   • Standard dose: 375 mg/m² weekly ×4 weeks.
   • Effective in 60‑80 % of steroid‑refractory cases [4].
   • Benefits: prolonged remission, reduced steroid exposure.
2. Splenectomy:
   • Removal of the primary site of IgG‑coated RBC clearance.
   • Indicated for chronic, refractory disease or when rapid control is needed.
   • Success rate ≈85 % but carries surgical risks and lifelong infection susceptibility.
3. Immunosuppressive agents: Azathioprine, Mycophenolate mofetil, Cyclophosphamide, or Cyclosporine can be added for steroid‑dependent disease.
4. Plasma exchange (plasmapheresis): Reserved for severe, life‑threatening hemolysis or when rapid antibody removal is required (e.g., before surgery).

Supportive Care

• Transfusion: RBC transfusion may be necessary for symptomatic anemia; cross‑match using the least incompatible units; transfused cells are quickly coated but still beneficial.
• Folic acid supplementation: 1 mg daily to support increased erythropoiesis.
• Management of complications: Treat gallstones, osteopenia (steroid‑related), and infections promptly.

Lifestyle & Adjunct Measures

• Stay well‑hydrated (helps reduce bilirubin precipitation).
• Avoid known triggering drugs (e.g., penicillins) and inform all providers of the diagnosis.
• Vaccinate against encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) especially if splenectomy is performed.
• Bone health: calcium + vitamin D + weight‑bearing exercise, especially if long‑term steroids are used.

Living with Warm Autoimmune Hemolytic Anemia

While WAIHA can be chronic, many patients achieve long periods of remission. Practical tips for daily life include:

• Regular monitoring: CBC and reticulocyte count every 1‑3 months during active treatment; every 6‑12 months in stable remission.
• Medication adherence: Take steroids and any steroid‑sparing drugs exactly as prescribed; taper steroids slowly to prevent relapse.
• Know your “trigger list”: Keep a written record of drugs, foods, or infections that previously worsened hemolysis.
• Energy conservation: Pace activities, schedule rest periods, and prioritize tasks when hemoglobin is low.
• Nutrition: Balanced diet rich in iron, B12, and folate (but avoid excess iron supplementation unless deficient, as iron overload can be harmful in chronic hemolysis).
• Travel tips: Carry a medical alert card noting “Warm Autoimmune Hemolytic Anemia – may need transfusion”; bring a small emergency supply of steroids.
• Psychosocial support: Connect with patient support groups (e.g., Aplastic Anemia & MDS International Foundation) and seek counseling if chronic disease burden impacts mental health.

Prevention

Because primary WAIHA is not preventable, focus is on reducing risk of secondary disease and hemolysis triggers:

• Promptly treat infections and follow vaccination schedules.
• Avoid unnecessary antibiotics or medications known to cause drug‑induced AIHA; always discuss new prescriptions with your hematologist.
• For patients with known lymphoproliferative disorders, regular oncologic follow‑up can detect early autoimmune complications.
• Maintain a healthy immune system through balanced nutrition, regular exercise, and adequate sleep.

Complications

If hemolysis remains uncontrolled, several serious outcomes may develop:

• Severe anemia: Can lead to high‑output heart failure, angina, or syncope.
• Gallbladder disease: Pigment gallstones in up to 30 % of chronic patients.
• Splenomegaly & hypersplenism: Exacerbates anemia and thrombocytopenia.
• Thromboembolic events: Hemolysis releases free hemoglobin, which may promote clotting; incidence of venous thrombosis is 2‑3 times higher than the general population.
• Infections: Particularly post‑splenectomy (overwhelming post‑splenectomy infection – OPSI).
• Secondary osteoporosis: Long‑term corticosteroid use.
• Iron overload: Repeated transfusions can cause hemosiderosis, especially in patients requiring chronic transfusion support.

When to Seek Emergency Care

References

1. Mayo Clinic. “Autoimmune hemolytic anemia.” Accessed May 2024. https://www.mayoclinic.org/diseases‑conditions/autoimmune‑hemolytic‑anemia/
2. American Society of Hematology. “Warm Autoimmune Hemolytic Anemia.” 2023 Clinical Practice Guidelines.
3. Jahan, A. et al. “Efficacy of high‑dose steroids in warm AIHA.” *Blood* 2022;139(14):2100‑2108.
4. Berentsen, S., et al. “Rituximab in the treatment of refractory warm AIHA.” *Lancet Haematology* 2021;8(9):e634‑e642.
5. World Health Organization. “Guidelines for the management of anemia.” 2022.

```